Introduction
The prevalence of chronic hepatitis C virus (HCV) infection in patients with cancer ranges from 1.5% to 32% (1). The availability of highly effective direct-acting antiviral (DAA) drugs, such as sofosbuvir/velpatasvir, represents a significant progress for patients with chronic HCV infection. However, the potential for drug–drug interactions (DDIs) is major with DAA drugs, especially in patients with chronic conditions such as cancer (2).
Crizotinib is a tyrosine kinase inhibitor (TKI) targeting anaplastic lymphoma kinase (ALK), ROS1, and mesenchymal–epithelial transition (MET) prescribed for non-small cell lung cancer (NSCLC) (3). This case report highlights a pharmacokinetic DDI between crizotinib and sofosbuvir/velpatasvir associated with cardiac toxicity.